US 12,129,297 B2
Antibodies against TIM3 and uses thereof
Xiao Min Schebye, San Carlos, CA (US); Mark J. Selby, San Francisco, CA (US); Michelle Minhua Han, Piedmont, CA (US); Christine Bee, San Francisco, CA (US); Andy X. Deng, San Mateo, CA (US); Anan Chuntharapai, Daly City, CA (US); Brigitte Devaux, Palo Alto, CA (US); Huiming Li, Lexington, MA (US); Paul O. Sheppard, Granite Falls, WA (US); Alan J. Korman, Piedmont, CA (US); Daniel F. Ardourel, Woodinville, WA (US); Ekaterina Deyanova, Lawrenceville, NJ (US); Richard Yu-Cheng Huang, Bridgewater, NJ (US); Guodong Chen, East Brunswick, NJ (US); Michelle Kuhne, San Francisco, CA (US); and Hong-An Truong, San Francisco, CA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 16/961,545
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed Jan. 11, 2019, PCT No. PCT/US2019/013246
§ 371(c)(1), (2) Date Jul. 10, 2020,
PCT Pub. No. WO2019/140229, PCT Pub. Date Jul. 18, 2019.
Claims priority of provisional application 62/616,723, filed on Jan. 12, 2018.
Prior Publication US 2022/0089720 A1, Mar. 24, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); G01N 33/6854 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70503 (2013.01)] 10 Claims
 
1. A human monoclonal antibody, which binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
(a) the VH comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 45, 413, and 414, respectively, and the VL comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 64, 66, and 69, respectively;
(b) the VH comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 45, 415, and 416, respectively, and the VL comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 64, 66, and 68, respectively; or
(c) the VH comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 45, 415, and 416, respectively, and the VL comprises a CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 64, 66, and 419, respectively.